Convalescent Plasma / St. Francis Medical Group - LARVOL DELTA

Convalescent Plasma in the Treatment of COVID 19 (clinicaltrials.gov) - P2; N=48; Completed; Sponsor: Saint Francis Care; Enrolling by invitation ➔ Completed; Trial completion date: Apr 2021 ➔ Aug 2020; Trial primary completion date: Dec 2020 ➔ Jul 2020

Trial completion • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease

Convalescent Plasma in the Treatment of COVID 19 (clinicaltrials.gov) - P2; N=45; Enrolling by invitation; Sponsor: Saint Francis Care; N=15 ➔ 45

Enrollment change • Infectious Disease • Novel Coronavirus Disease

Convalescent Plasma in the Treatment of COVID 19 (clinicaltrials.gov) - P2; N=15; Enrolling by invitation; Sponsor: Saint Francis Care; Not yet recruiting ➔ Enrolling by invitation

Enrollment open • Infectious Disease • Novel Coronavirus Disease

Convalescent Plasma in the Treatment of COVID 19 (clinicaltrials.gov) - P2; N=15; Not yet recruiting; Sponsor: Saint Francis Care

New P2 trial • Infectious Disease • Novel Coronavirus Disease